Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab alone or with cemiplimab in recurrent ovarian or MUC16+ cancers
NCT03564340Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2018
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of ubamatamab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose-Limiting Toxicity at 35 days, Treatment-Emergent Adverse Events at 2 years and 5 more. Started May 2018; status: recruiting.
02
Drugs
ubamatamab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03564340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564340.